114-LQP-IJCMR 20260903115715 Lumina Quest Publishing m.arslansohail@gmail.com Lumina Quest Publishing International Journal of Clinical and Medical Research Int. J. Clin. Med. Res. 3134-8831 10.66590/ijcmr https://lquestpub.com/archives.php?journal=international-journal-of-clinical-and-medical-research 06 30 2026 06 30 2026 3 1 10.66590/ijcmr20260301 https://lquestpub.com/articles-list.php?journal=international-journal-of-clinical-and-medical-research&volume=3&issue=1 PET Imaging in Alzheimer Disease: Diagnostic and Prognostic Applications Fahmida Khatoon Yassir Musa Zahid Balouch Syeda Misba Maqsood Komal Yousuf Muzammil Aftab Alzheimer Disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-β deposition, tau pathology, synaptic dysfunction, neuronal injury and cerebral atrophy. Positron Emission Tomography (PET) has transformed AD evaluation by enabling in-vivo visualization of molecular and metabolic abnormalities. 18F-Fluorodeoxyglucose (FDG) PET evaluates cerebral glucose metabolism, amyloid PET identifies fibrillar amyloid-β and tau PET provides information about neurofibrillary pathology. This review examines diagnostic and prognostic applications of PET in AD, particularly in mild cognitive impairment, atypical dementia, differential diagnosis, disease staging, progression prediction and treatment selection. Evidence indicates that amyloid PET is highly useful for establishing amyloid pathology, whereas tau PET is more closely associated with disease stage and clinical severity. FDG PET remains valuable for identifying patterns of neurodegeneration and distinguishing AD from other dementias. With the emergence of disease-modifying anti-amyloid therapies, molecular confirmation has become increasingly relevant to treatment decisions. Important limitations include cost, availability, radiation exposure, tracer-specific limitations, mixed pathology and interpretation variability. Future integration of PET with MRI, blood biomarkers and artificial intelligence may improve individualized diagnosis, prognosis and therapeutic monitoring. 06 30 2026 06 30 2026 47 50 10.66590/ijcmr2026030107 https://lquestpub.com/article/10.66590/ijcmr2026030107